Index

Acyclovir therapy 257
  CMV 158
  SCT patients 162, 167, 169
Acquired
  antibiotic resistance 231–33
  immunity, macrophages and, 49
  macrophage defects 56–57
Acute upper airway infections: **West JV** 215–230
Adaptive immunity to RSV disease 21–25
  humoral 21–22
  cell-mediated 22
  cytotoxic lymphocytes (CTL) 23
  T helper cells 23–25
Adenoviral pneumonia 120
Adenovirus 34, 35, 36, 141, 154, 170, 172, 224, 248, 251–253
  co-infection with *M. pneumoniae* 122
  serotypes and broncholitis obliterans 121–122
  SCT patients, 160
  vaccine 251, 255
Adhesions 5
Adult respiratory distress syndrome (ARDS) 155, 156, 168
Aggressive and persistent and bacteria in the lungs of CF patients 81–96
AIDS lung 1
Airway surface fluid (ASF) 2–5
Airways hyperactivity (AHR) 220
Alcaligenes xylosoxidans in CF lung 83
Alveolar macrophages (AM) 46, 283
  C. albicans, 54–55
  depleted mice 53
  HIV patients 51–52, 56
Amantadine 162, 163, 250
Ambisome and SCT patients 165, 169
Amikacin 242
Aminoglycosides 242
Amoxicillin/clavulanic acid 75
Amoxycillin-clavulanate resistance of *H. influenzae* 238
Ampicillin for Group B streptococcal pneumonia 68
Ampicillin-resistance and *H. influenzae* 237
Antenatal HIV diagnosis of mother, importance of 140
Antibiotic resistant bacteria, treatment of LRTI due to 231–245
Antibiotics before age 2 years, asthma 32
Antibody production defects 123–126
Antimicrobial resistance 109–110
Antiretroviral therapy (ART)
  HIV-infected children 133, 135–136, 139–140, 144, 146
Antituberculosis therapy
  HIV-infected children 142
Antiviral resistance measurements 103
Application of computed tomography (CT) in childhood respiratory infections: **Copley SJ** 263–279
Arbitrarily-primed PCR (AP-PCR) 108
Aspergillosis 8, 154, 169
  Grocott stain for 150
Aspergillus flavus and SCT patients 163–165
Aspergillus fumigatus
  CT or HRCT scans 270–271
  and SCT patients 163–165
Assessment of the child with recurrent chest infections: **Couriel J** 115–132
Asthma 8, 119
  and antibody defect often misdiagnosed 125
  and cough 218–220
  exacerbated by common colds 215
  infectious agents and aetiology of, 30
  naturally exposed to TB, less severe, 32
  and PCD 127
  and recurrent chest infections 115–116, 119
  viruses in 29–43
  protective effect of early exposure to infection 30–32
Azithromycin 76, 172, 238, 242

Bacille Calmette-Guérin (BCG) vaccination and HIV 142
Bacterial DNA (unmethylated cytosine-guanosine-rich areas known as CpG sequences) 3
Bacterial lung infections
  capsulate 63–80
  macrophage defences against 52–54
  molecular probes for diagnosis 105–110
  persistent and aggressive, in CF children 81–96

© The British Council 2002

Bacterial pneumonia
and CT scans 265–267
and HIV 137–138
and SCT 155–156
Bacterial restriction endonuclease analysis (BRENDA) genotypic typing scheme 108
Bordetella pertussis (whooping cough) 120
antibiotic resistance 240
Bordetella spp. and AM 56
Boyton RJ & Openshaw PJ: Defences (pulmonary) to acute respiratory infection 1–12
Branched chain DNA (bDNA) amplification methods 102–103
Breast feeding
immunoprotective effect of 14, 118, 140
reduces incidence of otitis media 223
Breathnach AS *see* **Heath PT**
Bronchiectasis 2
and HIV 137
and HRCT scans 274
and recurrent chest infections 115–116, 118
after acute pneumonia 120, 121, 122, 129
Bronchiolitis 13–28, 32
Broncho-alveolar lavage (BAL) 4, 9, 98, 123, 156, 158, 177, 178
Broncho-pulmonary dysplasia (chronic lung disease of prematurity) after ventilation 118
Broncholitis obliterans 121–122, 275–276
Brown JC: The management of croup 189–202
Budesonide 192, 194–196
Burkholderia cepacia 126
in CF lung 81, 83, 89–92
Burkholderia vietnamiensis in CF lung 91
Buttery J & Moxon ER: Capsulate bacteria and the lung 63–80

Candida albicans, 54–55
CT or HRCT scans 270–271
and SCT patients 165
Capreomycin 242
Capsulate bacteria and the lung: **Buttery J & Moxon ER** 63–80
Carbapenems for Group B streptococcal pneumonia 68
Cathelicidins 82
Cefotaxime 72, 236
Ceftriaxone 72, 236, 242
Cefuroxime 75
Cellular immunity defects (T cell deficiencies) 124, 126
Cephalosporins
second generation 75
third generation 72, 75, 78, 236–239
Cerebral palsy 130
Chemotherapy prior to SCT, respiratory infections following 151
Chlamydia
psittaci 259
pneumoniae 35, 116, 240, 258–259
diagnosis 106, 107
trachomatis 258–259
Chronic
granulomatous disease (CGD) 126
lung disease of prematurity (broncho-pulmonary dysplasia) 118
obstructive pulmonary disease (COPD) 74, 75, 98, 112
suppurative lung disease 120–130
and antibiotic-resistant bacteria (including CF patients) 234
cystic fibrosis 121
bronchiectasis 121
investigation of 128–130
organisation of care 130
Cigarette smoking 57, 71
parental and LRTIs 118
and otitis media 223
Ciliary function disorders 120, 126–127
Ciprofloxacin 72, 76, 239, 242
Clarithromycin 238, 258
Clindamycin 72, 239
for Group B streptococcal pneumonia 68
Co-trimoxazole 259
Colds (common) 215–220
management 216–218
Collectins 4, 18, 45
Community-acquired pneumonia (CAP) 52, 63, 70, 71–72, 77, 98, 237, 239,
antibiotic resistance 233–234
Complement deficiency 124
Computed tomography (CT) and
high resolution (HRCT) 129, 263, 268–269, 271–276
application of in childhood respiratory infections 169–170, 263–279
adenovirus pneumonia 252
empyema 205, 210–211
HIV patients 137
immunocompromised children 271–273
recurrent respiratory tract infections 273–274
for revealing bronchiectasis 129
sequelae of respiratory infections 275

Congenital
abnormalities of respiratory tract 115–116, 118
abnormalities of the lungs 127–128
heart disease and recurrent chest infections 118
macrophage defects 55–56
Copley SJ: Application of computed tomography in childhood respiratory infections 263–279
Coronavirus 34, 35, 36, 116, 216
Coryzal illnesses 215
Cotrimoxazole (trimethoprim-sulfamethoxazole) for PCP prophylaxis 137, 139, 140
Cough in children
and asthma 218–220
post-infective 119–120
Cough receptor sensitivity (CRS) 220
Couriel J: Assessment of the child with recurrent chest infections 115–132
Coxiella burnetti (Q fever) 259
Croup, management of 189–202
Cycloserine 242
Cystic fibrosis (CF), children with 1–3, 120, 121, 127
diagnostic tests 129
persistent and aggressive bacteria in the lungs of 81–96
penicillin-resistant *Staph. aureus* infections 238–239
recurrent chest infections 115–116
sputum DNA analysis 3
use of gene transfer systems 57
Cystic fibrosis transmembrane conductance regulator (CFTR) 2, 81, 86
Cytomegalovirus (CMV)) 256, 272
antibiotic resistance 103
SCT patients 156–158, 167, 169, 170, 172
immunocompromised patients, 99, 123, 154
with PCP and HIV 137, 139–140, 141, 146, 272–273
Cytosine-guanosine-rich (unmethylated) areas - CpG sequences 3
Cytospins 170
Cytotoxic lymphocytes (CTL) 23

Defences (pulmonary) to acute respiratory infection 1–12
macrophages 45–61
Defensins 3–5
in CF lung, 82
Dendritic cells (DC) 46–47
and RSV 50–51
Dexamethasone 192–196, 198
Diabetes, type 1, 8
Diagnosis of respiratory tract infection, recent advances 97–114
differential diagnosis 97, 119–120
molecular probes, 98–111
Differential diagnosis of recurrent chest infections 119–120
DiGeorge syndrome 122, 126
Dihydropteroate synthase (DHPS) gene mutations 181–182
DNA
amplification fingerprinting (DAF) 108
chip technology 111
Down's syndrome 122
Doxicycline 72
Drug resistant organisms, treatment of infections due to 231–245

Empyema
radiological perspectives in 203–214
CT scans 265, 266
Enterobacter cloacae 155
Enteroviruses 34, 35
Enzyme-linked immunospot (ELISPOT) assays to detect antigen-specific T-cells 112
Eosinophil cationic protein 20
Eosinophils and RSV bronchiolitis 19–20
Epidemic MRSA (E-MRSA) in UK hospitals 238–239
Epidemiology of viruses causing primarily respiratory disease 34–36
Epinephrine(L-) and croup 198
Epstein-Barr virus (EBV) 256
EBV-specific cytotoxic T-cells, 167
in pathogenesis of LIP, 143, 144
in SCT patients 154, 170, 172
related lymphoproliferative disease 168
Erythromycin 70, 258–259
for MRSA 239
resistance in *H. influenza*, 228, 238, 240
resistance in *Strep. pneumoniae* 223
Escherichia coli and HIV 137, 138
ET-12 (Edinburgh-Toronto), highly transmissible lineage in *B. cepacia* genomovar III, 90–92
Ethionamide 242

F protein 13, 16–18, 22, 24, 248
Flow cytometry 112

Flucloxacillin 239
Flucytosine and SCT patients 165, 169
Fluorescent antibody technique 17
Fluoroquinolones 72, 242
Fluoroscopy for empyema 208
Foscarnet in CMV 103, 158, 256
Fungal infections
  and CT/HRCT scans 270–271
  and HIV 54–55
Fungi
  macrophage defences against 54–55
  molecular probes for diagnosis 110–111

G protein 13, 15, 16, 18, 21, 24, 248
Ganciclovir
  for CMV 103, 158, 256
  in SCT patrients 169, 172
Gastro-oesophageal reflux 121, 128, 130
Gaucher's syndrome 55–56, 57
Gene amplification probes 99
Gene probes for resistance 109
Gene therapy (TNF) 56, 58
Gene transfer systems 57
Genotypic typing schemes 107–108
Gentamicin 239, 242
Gibb DM *see* **Graham SM**
Glucocorticoids therapy for croup 191–196
Gordon SB & Read RC : Macrophage defences against respiratory tract infections 45–61
Graft versus host disease (GvHD) 153, 156, 160, 163, 166, 167
Graham SM &Gibb DM: HIV disease and respiratory infection in children 133–150
Grepafloxacin 72
Grocott's stain
  for *Aspergillus* hyphae 150
  for *P. carinii* 177
Group A β-haemolytic *Streptococcus* (GABHS) pharyngitis 221
Group B streptococcal pneumonia 65–68

Haemoglutinin (H) 248
Haemophilus influenzae 5, 116, 125, 223
  ampicillin-resistance 237
  antibiotic resistance genes 110
  chronic suppurative lung disease 121
  HIV-infected children 137–138
  (non-capsulate) in CF lung 83, 84
  and otitis media 224
  and SCT patients 155
  type b (Hib)
    conjugate vaccine 64–65, 74, 78, 137–138, 237
  vaccine development 63, 138
Haemopoietic stem cell transplantation (SCT) in children, respiratory infections following 151–174
Hart CA & Winstanley C: Persistent and aggressive bacteria in the lungs of cystic fibrosis children 81–96
Heath PT & Breathnach AS: Treatment of infections due to resistant organisms 231–245
Heliox in croup management 199
Herpes simplex virus (HSV)
  CT scans 272
  and SCT patients 154, 162, 169
High resolution computed tomography (HRCT) *see also* Computed tomography (CT)
High-resolution computed tomography (HRCT) 129, 263, 271–276
  immunocompromised children 271–273
  recurrent respiratory tract infections 273–274
  for revealing bronchiectasis 129
  sequelae of respiratory infections 275
Highly active antiretroviral therapy (HAART) for HIV patients 135–136, 139–140
Human immunodeficiency virus (HIV) and respiratory infection in children: **Graham SM &Gibb DM** 133–150
  African children 137
  diagnosis in infancy 135
  fungal infections, 54–55
  high-resolution computed tomography (HRCT) 272–273
  M. tuberculosis 52, 54
  macrophage defence against 51–52, 56
  P. carinii 54–55
  prevention of childhood 134–135
  mother-to-child transmission 135–136
  related morbidity and mortality 135–136
Hospital-acquired pneumonia 234
Human
  herpes virus 6 (HHV6)
    and SCT patients 163, 167, 287
  herpes virus 8 (HHV8)
    and HIV 137
  metapneumovirus (hMPV) 252
Humidification for croup 196–197
Hybridisation protection assay (HPA) 107

Iatrogenic (drug) induced acquired macrophage defects 57
Idiopathic pneumonia syndrome (IPS) 167–168

Imipenum 242
Immune system and bowel flora, antibiotics and asthma, 32
Immunity
  innate and specific
    to infection in the lung 1–12
    to RSV disease 17–25
  macrophages and 47–49
Immunocompromised child
  and CMV, 99
  and fungal infections 110–111
  and *P. carinii* pneumonia (PCP) 175–188
  prior to SCT, respiratory infections following 151–174
Immunodeficiences, primary 120, 122–126
  due antibody production defects 123
  due to HIV/AIDS 123
Immunodeficiency syndromes and recurrent chest infections 115–116
Immunofluoresence, diagnosis using 99, 111
Immunoprotective effect of breast feeding 14, 118, 140
  reduces incidence of otitis media 223
Influenza A and B 32, 34, 35, 36, 116, 154, 170, 216, 224
  and asthma exacerbations, 39
  and croup 189–202
  and epidemics 248–250
  and HIV 141
  and SCT patients 162–163
  Taqman technology for detection and differentiation, 102
  vaccines against 250
Inhaled foreign bodies and persistant cough 120, 121
Innate immunity 2–5
  to RSV disease 17–21
  macrophages and, 47–49
Intercellular adhesion molecule-1 (ICAM-1) 5, 19, 39
  receptor and rhinovirus 254
Interferons (IFNs) 4–5, 24, 33, 53, 54
Interstitial lung disease and CT scans 276
Invasive pulmonary aspergillosis (IPA)
  CT diagnosis 272
  in SCT patients 163–165
Isoniazid for pulmonary TB 240, 242
Isospora belli infections and cotrimoxazole treated HIV-infected children, 140
Itraconazole or itraconazole/fluconazole and SCT patients 165, 169

Johnston SL *see* **Message SD**

Kaposi's sarcoma and AIDS/HIV-infection 146
  and novel herpes virus 103
Kartagener's syndrome 127
King S & Thomson A: Radiological perspectives in empyema 203–214
Klebsiella spp. 10, 155
  and HIV 137, 138
  and nosocomical pneumonia, 52–53
Knockout mice 4, 8, 10

Lactoferrin 3
Legionella pneumophila 53–54, 91, 108, 155, 170, 259
  and hospital-acquired pneumonia 234
  and TB 54
  typing 109
  viable or non-viable differentiation by RT-PCR 107
  Levofloxacin 72
Ligase chain reactions (LCR) 101, 106, 107
Linezolid 239
Lipopolysaccharide (LPS) 3, 4
Liposomal amphotericin 172
Lowenstein-Jensen culture media 105
Lower respiratory tract infections (LRTIs) 65, 70, 117–119
  indications for CT 265
Lymphocytic interstitial pneumonitis (LIP) and HIV 137
Lymphoproliferative disease (LPD) and SCT patients 154

MacLoed's syndrome 122, 275
Macrolides 72, 76, 238, 242, 259
Macrophage defences against respiratory tract infections: **Gordon SB &Read RC** 45–61
Macrophages
  defences against viruses 50–52
  defences against bacteria 52–54
  RSV bronchiolitis and 19–20
  types and origins, 45–47
    alveolar macrophages (AM) 46, 51–52
    dendritic cells (DC) 46–47, 50–51
    lung macrophages 45–46
    monocytes 47
Magnetic resonance imaging (MRI) for empyema 211–212
Malaria and HIV treatment 141
Malignant lymphona and HIV-infection 146

Malnutririon 57
Management of croup: **Brown JC** 189–202
Management of respiratory disease post SCT 171–172
Mannan-binding lectin (MBL) 4
McNamara P & Smyth RL: Pathogenesis of respiratory syncytial virus (RSV) in childhood 13–28
Measles
and HIV 137, 141
and SCT patients 163
leading to pneumonia 255–256
vitamin A therapy 255–256
Meningitis 74, 77–78
due to *N. meningitidis* 77–78
vaccines against 78
Meropenum 242
Message SD & Johnston SL: Viruses in asthma 29–43
Metapneumovirus in The Netherlands 34
Methicillin-resistant *Staph. aureus* (MRSA) infections 109, 238–239
Methicillin/flucloxacillin 239
Minimal inhibitory concentration (MIC) of an antibiotic 232
Molecular epidemiology 101–102
Molecular probes for diagnosis 98–111
bacteria 105–110
fungi 110–111
viruses 98–105
Monoclonal antibodies, anti-B-cell 167
Moraxella catarrhalis 116, 224, 238
Mother-to-child transmission of HIV infection 146–147
Moxon ER *see* **Buttery J**
Multi-drug resistant tuberculosis (MDR-TB) 241–243
Multicentre Allergy Study (MAS) Group 30
Multiplex PCR methods 101
Mycobacterial infections and SCT patients 166
Mycobacterium avium-intracellulare complex (MAIC) in HIV-infected children 135, 143, 272
Mycobacterium bovis Bacille-Calmette-Guérin strain detection 106
Mycobacterium leprae antibiotic resistance gene 110
Mycobacterium tuberculosis 9, 10
drug therapy and resistant strains 110, 240–242
earlier detection by ELISPOT than tuberculin skin test 112
identification 105–107
and HIV 52, 54
macrophage defences against 54
Mycoplasma pneumoniae 35, 116, 240, 257–258
and adenovirus (very damaging) 122
and croup 189–202
and diagnosis with HRCT 268
Myint S: Recent advances in the rapid diagnosis of respiratory tract infection 97–114

Natural killer (NK) cells in RSV infection 5, 20, 21
Neisseria meningitidis CAP 77–78
antibiotic resistance genes 110
Neuraminidase (N) 248
Neurodevelopmental defects 130
Neurogenic-mediated inflammation 25
Neutrophils and RSV bronchiolitis, 18–19
Nitric oxide synthetase (iNOs) in CF lung 82
Nitric oxide-dependent mechanism 54
Nocardiosis (*Nocardia asteroides*)
CT scan 272
and HIV 137
Non-amplification probes 99
Non-immunological factors in severity of RSV disease
Non-invasive markers for diagnosis 112
Nosocomical
outbreaks in CF patients 90
pneumonia, 52–53
Novel agents of disease (novel respiratory viruses), detection of 103–104
Nucleic acid sequence-based amplification (NASBA) 102
mycobacterium identification, 106

Obliterative bronchiolitis and CT scans 275–276
Oesophagial atresia 128
Ofloxacin 76
Openshaw PJ *see* **Boyton RJ**
Oryza sativa variants 108
Otitia media (OM) 74, 223–227
acute (AOM) 223–225
and conjugate Hib vaccine, 73
recurrent OM 225
with effusion (OME) 223, 226

Pandoraea spp. in CF lung 89
Papanicolaou stain 170

Parainfluenza virus (PIV) 34, 35, 36, 116, 170, 216, 224, 248, 252–253, 255
and croup 189–202
typing by multiplex PCR 101
Pathogenesis of respiratory syncytial virus (RSV) in childhood: **McNamara P & Smyth RL** 13–28
Penicillin and
erythromycin resistance in *Strep. pneumoniae* 223, 235–236
Group B *Streptococcal* pneumonia 68
meningitis, 77
resistance 223, 235–238
Pericarditis 75
Peripheral blood mononuclear cells (PBMCs) 23, 24, 33
and TB 54
Persistent and aggressive bacteria in the lungs of cystic fibrosis children: **Hart CA & Winstanley C** 81–96
Phagocyte defects 124, 126
Pharyngitis management 221–222
Piperacillin 242
Plasmid DNA profiles 108–109
Pneumococcal conjugate vaccines
conjugate vaccines in otitis media 226–227
for HIV-infected children 138–139
Pneumococcus – *Streptococcus pneumoniae* 68–73
Pneumocystis carinii: **Wakefield AE** 175–188
Pneumocystis carinii 52, 54–55, 111, 123
CT scans 272
detection using PCR 110
diagnosis 98
drug-resistant strains, emergence of 181–182
genome of 183–184
genotyping 178
and HIV-infected children 133, 135, 137–141
molecular detection 177–178
primary infection 182–183
SCT patients 154, 165–166
transmission 179–181
Pneumonia due to viral and atypical organisms and their sequelae: **Smyth A** 247–262
Pneumovax® Hib vaccine 125, 129
Polymerase chain reaction
restriction endonuclease (PCR-RE) 101
restriction fragment length polymorphism (PCR-RFLP) analysis 102
single-strand-conformation polymorphism (PCR-SSCP) analysis 101–102
Polymerase chain reaction (PCR) for
detection and quantification of
viruses 99–104
bacteria 105–110
fungi 110–111
detecting CMV 158
in SCT patients to detect CMV, adenovirus, EBV and mycobacteria 170
Polyribosylribitol phosphate (PRP), primary virulence determinant 73, 75–76
Post-transplantation lymphoproliferative disease (PTLD) and SCT patients 167
Prednisone 139
Primary ciliary dyskinesia (PCD) 127
Probe amplification techniques 101
Procalcitonin 248
Protein-polysaccharide conjugate vaccines 63–65
Protozoal and SCT patients 165–166
Prussian blue stain 170
Pseudomonas aeruginosa 53, 56, 155
alginate-producing mucoid phenotype 87
antibiotic resistance 242–243
and CF 81, 83–88, 90, 242–243
genomic sequence of, 85
genomic island-1 (PAGI-1) 88
and HIV 137
typing 109
Pulmonary defences to acute respiratory infection: **Boyton RJ & Openshaw PJ** 1–12
Pulmonary
Kaposi's sarcoma and HIV 137
surfactant 17–18
tuberculosis (PTB)
antibiotic resistance 234
and HIV 137, 141–143
see also *M. tuberculosis* 137
Pulsed field gel electrophoresis (PFGE) 85
Pyocyanin 86, 88
Pyrazinamide 242

Qβ replicase amplification 101
Quantification of viral load 102–103
Quinolones 238, 259
resistance to 238, 242
Quinupristin-dalfopristin 239

Racemic epinephrine and croup 197–198
Radiation hazards of thoracic imaging 205–206
Radiological perspectives in empyema: **King S & Thomson A** 203–214

Radiological signs associated with specific respiratory infections 169
Ralstonia picketii in CF lung 89
Random amplified polymorphic DNA (RAP-D) method 85, 108
Read RC *see* Gordon SB
Recent advances in the rapid diagnosis of respiratory tract infection: **Myint S** 97–114
Recurrent chest infections 115–116, 118
  assessment of the child with 115–132
Rep-PCR, PCR amplification of region between repetitive elements 109
Repetitive DNA in bacterial genomes 109
Representational differential analysis (RDA) 103–105
Resistance in *Strep. pneumoniae* 72
Resistant organisms, treatment of infections due to 231–245
Respiratory complications after SCT 168–172
  diagnosis 168–171
  management 171–172
Respiratory tract infections
  following haemopoietic stem cell transplantation (SCT) in children: **Veys P & Owens C** 151–174
  in HIV-infected children 133–150
    management and causes 136–146
  macrophage defences against 45–61
  pulmonary defences to acute 1–12
Respiratory syncitial virus (RSV) 4, 5, 9–10, 29, 32–33, 36, 116, 216, 248, 252
  asthma and 29–43
  and croup 189–202
  genome 16
  HIV-infected children 137, 141
  and macrophage (dendritic cells) defence against 50–51
  pathogenesis in childhood 13–28
  pneumonia
    in SCT patients 158–160
    causing LRTI 117
  SCT patients 154, 170
  vaccine used to prevent otitis media 224
Restriction fragment length polymorphism (RFLP) 101
Reverse transcriptase (RT) enzyme 98, 102
Rhinovirus 35, 36, 116, 224, 248, 253–254
  asthma exacerbations and 29, 32, 35, 36, 254
  common cold 216
  vaccination against 37–39
  and otitis media 224
Rhodococcus spp. typing 109
Ribavirin 160
  i.v. for adenovirus 252
  for PIV 162
  SCT patients 163
Ribotyping for epidemiological purposes 109
Rifamicin 239, 242, 259
Rituximab 167

Salmonella spp. and HIV 137, 138
Sarcoidosis 2, 8
Sepsis syndrome, 56
Septrin for PCP in SCT patients 169, 172
Serratia marcascens 126
Severe combined immune deficiency (SCID) 123–124, 126
  state induced for SCT 151–174
Sinusitis 74
Smyth A: Pneumonia due to viral and atypical organisms and their sequelae 247–262
Smyth RL *see* McNamara P
Sparfloxacin 72, 76
Specific immunity to infection in the lung 5–10
Staphylococcal species identification 108
Staphylococcus aureus 126
  antibiotic resistance 109, 110, 238–239
  chronic suppurative lung disease 121
  in CF lung 83, 84, 238–239
  genotypic typing 107
  HIV 52, 137, 138
  methicillin-resistant (MRSA) infections 238–239
  penicillin-resistant infections in CF children 238–239
  SCT patients 155
Staphylococcus epidermidis antibiotic resistance 109, 110
Stem cell transplantation (SCT), haemopoietic and HIV 141
  prophylactic medications 169–170
Stenotrophomonas maltophilia in CF lung 83
Steroids, 139, 140
Steven-Johnson reaction in HIV-infected children 142
Strand displacement amplification for M. tuberculosis detection 106
Streptococcus agalactiae 65–68
Streptococcus mitis 155
Streptococcus pneumoniae 68–73, 116, 125
  and AM 56
  antibiotic resistance 235–237
  and HIV 52, 56, 137, 138
  immunofluorescence detection 111, 255

management 72
and measles 255
and otitis media 223–224
and SCT 155
vaccine development 63, 72–73
Streptococcus pyogenes strains identification 108
Substance P 25
Sudden infant death syndrome (SIDS) and *P. carinii* infection 182–183
Suppression subtraction hybridisation (SSH) 103–105
Surfactant proteins (SP-A, B, D) 4, 17–18, 52, 54
Swallowing difficulties 121

T cell deficiencies 124, 126
Taqman technology for detection and differentiation of viral load, 102
Targeted protein delivery to macrophages 57
Tazobactum 242
Teicoplanin for MRSA 239
Tetracycline 240, 259
Thermus thermophilus DNA polymerase 99
Thiacetazone and Steven-Johnson reaction in HIV-infected children 142
Toll-like receptor 4 (TLR4) 18
Tonsillitis management 221–222
Tracheal antimicrobial peptide (TAP) 4
Tracheo-oesophageal fistula 128
Transcription-based amplification system 102
Transcription-mediated amplification (TMA) systems 107
Transthoracic needle biopsy for PCP diagnosis 98
Treatment of infections due to resistant organisms: **Heath PT & Breathnach AS** 231–245
Trichosporon fusarium and SCT patients 165
Trimethoprim-sulfamethoxazole (Cotrimoxazole) 240
for PCP prophylaxis 137, 139, 140
for PCP in SCT patients 165
Tuberculosis and persistant cough 128
see also Mycobacterium tuberculosis
Tuberculosis, natural exposure reduces severity of asthma, 32
Tumour necrosis factor (TNF) 3, 5, 6, 20, 53, 54
gene therapy for pulmonary infections 58
gene therapy for sepsis syndrome, 56
Type III secretion systems (TTS) 88
Typing of isolates 107–109

Ultrasound in empyema management 204, 209–210
Upper respiratory tract infections (URTIs) 116–117, 215–230
Ureaplasma urealyticum 257–258

Vaccination
against Hib for HIV-infected children 76, 138
against meningitis 78
to prevent otitis media 224, 226–227
against rhinovirus 37–39
against *Strep. pneumoniae* 72–73
against Group B streptococci 67
targeting capsular polysaccharides 63–80
against TB, Bacille Calmette-Guérin (BCG) and HIV 142
'vaccine-probe' studies, 65, 74
Vancomycin 72, 237
for MRSA 239
Varicella (chicken pox) 256–257
immunosuppressed patients 257
Varicella zoster virus (VZV) 163, 272
Veys P & Owens C: Respiratory infections following haemopoietic stem cell transplantation in children 151–174
Videothorascopic surgery (VATS) 171, 203
Viral and atypical organisms, pneumonia due to 247–262
Viral pneumonia
indications for CT 267–268
and HIV 137, 141
Virus-induced exacerbation of asthma mechanisms of and treatment 36–39
Virus-induced wheezing, mechanisms of 36–37
Viruses in asthma: **Message SD & Johnston SL** 29–43
Viruses
macrophage defences against 50–52
molecular probes for diagnosis 98–105

Wakefield AE: *Pneumocystis carinii* 175–188
West JV: Acute upper airway infections 215–230
Wheezing illness in infancy 32–37

Winstanley C *see* **Hart CA**
Wright-Giemsa stain 170

X-linked agamma-globulinaemia (XLA or Bruton's disease) 123–124, 125–126
X-ray assessment of severity and distribution of lung involvement, 129

Zanamivir 163, 250
Zehl-Neelsen (ZN) stain and false-negatives 105–106, 170
Zoster varicella virus (VZV) 163, 272
Zygomycetes and SCT patients 165